Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1953 1
1954 2
1965 1
1970 1
1972 2
1973 3
1974 3
1975 1
1976 5
1977 2
1978 2
1979 1
1980 3
1981 5
1982 7
1983 4
1984 8
1985 7
1986 13
1987 9
1988 8
1989 6
1990 10
1991 5
1992 5
1993 4
1994 6
1995 11
1996 15
1997 8
1998 5
1999 11
2000 10
2001 6
2002 8
2003 8
2004 7
2005 12
2006 8
2007 3
2008 3
2009 4
2010 7
2011 8
2012 13
2013 12
2014 12
2015 16
2016 15
2017 8
2018 7
2019 8
2020 13
2021 11
2022 3
2023 3
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

365 results

Results by year

Filters applied: . Clear all
Page 1
SPIRIT 2013 statement: defining standard protocol items for clinical trials.
Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. Chan AW, et al. Among authors: dore cj. Ann Intern Med. 2013 Feb 5;158(3):200-7. doi: 10.7326/0003-4819-158-3-201302050-00583. Ann Intern Med. 2013. PMID: 23295957 Free PMC article.
Guidelines for the Content of Statistical Analysis Plans in Clinical Trials.
Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E, Doré C, Williamson PR, Altman DG, Montgomery A, Lim P, Berlin J, Senn S, Day S, Barbachano Y, Loder E. Gamble C, et al. Among authors: dore c. JAMA. 2017 Dec 19;318(23):2337-2343. doi: 10.1001/jama.2017.18556. JAMA. 2017. PMID: 29260229 Free article.
Total Ankle Replacement Versus Arthrodesis for End-Stage Ankle Osteoarthritis: A Randomized Controlled Trial.
Goldberg AJ, Chowdhury K, Bordea E, Hauptmannova I, Blackstone J, Brooking D, Deane EL, Bendall S, Bing A, Blundell C, Dhar S, Molloy A, Milner S, Karski M, Hepple S, Siddique M, Loveday DT, Mishra V, Cooke P, Halliwell P, Townshend D, Skene SS, Doré CJ; TARVA Study Group; Brown R, Butler M, Chadwick C, Clough T, Cullen N, Davies M, Davies H, Harries B, Khoo M, Makwana N, Murty A, Najefi A, O'Donnell P, Raglan M, Thomas R, Torres P, Welck M, Winson I, Zaidi R. Goldberg AJ, et al. Among authors: dore cj. Ann Intern Med. 2022 Dec;175(12):1648-1657. doi: 10.7326/M22-2058. Epub 2022 Nov 15. Ann Intern Med. 2022. PMID: 36375147 Clinical Trial.
Optimal timing of anticoagulation after acute ischemic stroke with atrial fibrillation (OPTIMAS): Protocol for a randomized controlled trial.
Best JG, Arram L, Ahmed N, Balogun M, Bennett K, Bordea E, Campos MG, Caverly E, Chau M, Cohen H, Dehbi HM, Doré CJ, Engelter ST, Fenner R, Freemantle N, Hunter R, James M, Lip GY, Murray ML, Norrving B, Sprigg N, Veltkamp R, Zaczyk I, Werring DJ; OPTIMAS investigators. Best JG, et al. Among authors: dore cj. Int J Stroke. 2022 Jun;17(5):583-589. doi: 10.1177/17474930211057722. Epub 2022 Jan 12. Int J Stroke. 2022. PMID: 35018878
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.
Cohen H, Hunt BJ, Efthymiou M, Arachchillage DR, Mackie IJ, Clawson S, Sylvestre Y, Machin SJ, Bertolaccini ML, Ruiz-Castellano M, Muirhead N, Doré CJ, Khamashta M, Isenberg DA; RAPS trial investigators. Cohen H, et al. Among authors: dore cj. Lancet Haematol. 2016 Sep;3(9):e426-36. doi: 10.1016/S2352-3026(16)30079-5. Lancet Haematol. 2016. PMID: 27570089 Free PMC article. Clinical Trial.
Ophthalmic statistics note 10: data transformations.
Bunce C, Stephenson J, Doré CJ, Freemantle N; Ophthalmic Statistics Group. Bunce C, et al. Among authors: dore cj. Br J Ophthalmol. 2016 Dec;100(12):1591-1593. doi: 10.1136/bjophthalmol-2016-308824. Epub 2016 Jul 18. Br J Ophthalmol. 2016. PMID: 27432738 No abstract available.
Tissue-Engineered Disease Modeling of Lymphangioleiomyomatosis Exposes a Therapeutic Vulnerability to HDAC Inhibition.
Pietrobon A, Yockell-Lelièvre J, Melong N, Smith LJ, Delaney SP, Azzam N, Xue C, Merwin N, Lian E, Camacho-Magallanes A, Doré C, Musso G, Julian LM, Kristof AS, Tam RY, Berman JN, Shoichet MS, Stanford WL. Pietrobon A, et al. Among authors: dore c. Adv Sci (Weinh). 2023 Sep;10(26):e2302611. doi: 10.1002/advs.202302611. Epub 2023 Jul 3. Adv Sci (Weinh). 2023. PMID: 37400371 Free PMC article.
Ophthalmic statistics note 6: effect sizes matter.
Cook JA, Bunce C, Doré CJ, Freemantle N; Ophthalmic Statistics Group. Cook JA, et al. Among authors: dore cj. Br J Ophthalmol. 2015 May;99(5):580-1. doi: 10.1136/bjophthalmol-2014-306303. Epub 2015 Feb 26. Br J Ophthalmol. 2015. PMID: 25722490 Free PMC article. No abstract available.
Ophthalmic statistics note 8: missing data--exploring the unknown.
Bunce C, Quartilho A, Freemantle N, Doré CJ; Ophthalmic Statistics Group. Bunce C, et al. Among authors: dore cj. Br J Ophthalmol. 2016 Mar;100(3):291-4. doi: 10.1136/bjophthalmol-2015-307821. Epub 2015 Dec 30. Br J Ophthalmol. 2016. PMID: 26719490 Free article. No abstract available.
365 results